Why the study?
National prescribing patterns and barriers to using thrombolytic agents for pulmonary embolism, especially during actual or imminent cardiac arrest, needed characterization.
Most surveyed critical care professionals use thrombolytics for cardiac arrest secondary to massive pulmonary embolism, with use predicted by working in a pulmonary/critical care environment and provider comfort level.
Answers are grounded in this paper and cite their sources.
Provider specialty and comfort predict thrombolytic use in PE arrest; hypothesis-generating and should not yet change practice.
Objectives: This survey sought to characterize the national prescribing patterns and barriers to the use of thrombolytic agents in the treatment of pulmonary embolism, with a specific focus on treatment during actual or imminent cardiac arrest. Design: A 19-question international, cross-sectional survey on thrombolytic use in pulmonary embolism was developed, validated, and administered. A multivariable logistic regression was conducted to determine factors predictive of utilization of thrombolytics in the setting of cardiac arrest secondary to pulmonary embolism. Setting: International survey study. Subjects: Physicians, pharmacists, nurses, and other healthcare professionals who were members of the Society of Critical Care Medicine. Interventions: None. Measurements and Main Results: Thrombolytic users were compared with nonusers. Respondents ( n = 272) predominately were physicians (62.1%) or pharmacists (30.5%) practicing in an academic medical center (54.8%) or community teaching setting (24.6%). Thrombolytic users ( n = 177; 66.8%) were compared with nonusers ( n = 88; 33.2%) Thrombolytic users were more likely to work in pulmonary/critical care (80.2% thrombolytic use vs 59.8%; p < 0.01) and emergency medicine (6.8% vs 3.5%; p < 0.01). Users were more likely to have an institutional guideline or policy in place pertaining to the use of thrombolytics in cardiac arrest (27.8% vs 13.6%; p < 0.01) or have a pulmonary embolism response team (38.6% vs 19.3%; p < 0.01). Lack of evidence supporting use and the risk of adverse outcomes were barriers to thrombolytic use. Working in a pulmonary/critical care environment (odds ratio, 2.36; 95% CI, 1.24–4.52) and comfort level (odds ratio, 2.77; 95% CI, 1.7–4.53) were predictive of thrombolytic use in the multivariable analysis. Conclusions: Most survey respondents used thrombolytics in the setting of cardiac arrest secondary to known or suspected pulmonary embolism. This survey study adds important data to the literature surrounding thrombolytics for pulmonary embolism as it describes thrombolytic user characteristic, barriers to use, and common prescribing practices internationally.
No takes yet. Share an insight, caveat, or question.
Rech et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: